FDA Grants Fast Track Designation to HP518 for AR+ TNBC
The FDA has granted fast track designation to HP518 for androgen receptor–positive triple-negative breast cancer.
Related Articles
MD Anderson and Rice launch initiative to advance cancer-focused operations research
The University of Texas MD Anderson Cancer Center and Rice University today announced the launch of the Center for Operations Research in Cancer, a joint…
Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors in NSCLC, according to findings…
Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays – The Cancer Letter
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy…
Fundamental Research Paved the Way for the Development of Vorasidenib
Vorasidenib is a new promising clinical treatment for gliomas. However, this recent breakthrough in the treatment of brain tumors is only a snapshot of a…
Cancer rarely travels alone: Addressing the accumulation of risk and early mortality for older adults with advanced lung cancer
Lung cancer kills more people globally than any other cancer [1]. In the United States, it is responsible for more cancer-related deaths than breast, prostate,…
Science Talk – “Our underlying motivation has an emotional core” – en
Childhood cancer treatment is challenging, with certain cancer types proving particularly difficult to treat. Although researchers have made significant progress, the outlook for children with…
Stakeholder Connect | Supreme Court Decisions and Their Impact on the FDA and Patients’ Lives: The Overruling of Chevron – Friends of Cancer Research
What is Chevron deference, how did it come to be, and what were the implications for FDA? Chevron deference was established by the 1984 Supreme…
Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC
Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.
Abnormal Uterine Bleeding and the Risk of Endometrial Cancer
Researchers developed a predictive model to assess endometrial hyperplasia and cancer risk in patients with recurrent abnormal uterine bleeding. Learn more.
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In the phase III HARMONi-2 study conducted in China, presented at the IASLC 2024 World Conference on Lung Cancer, the bispecific antibody ivonescimab was compared…